PHARMACOLOGY, MEDICAL REPORTS, ORTHOPEDIC, AND ILLNESS DETAILS (COMORBID)
Vol. 3 No. 4 (2024): OCTOBER

THE POTENTIAL ACTIVITY OF ASIATICOSIDE FROM AKAR MANIS (Glycyrrhiza glabra) AS HYPOLIPEMIC

Prasetyawan, Fendy (Unknown)
Saristiana, Yuneka (Unknown)
Salmasfattah, Novyananda (Unknown)
Mildawati, Ratna (Unknown)
Mayasari, Shinta (Unknown)



Article Info

Publish Date
07 Feb 2025

Abstract

Asiaticoside, a bioactive compound derived from Glycyrrhiza glabra (licorice root), has garnered attention for its potential as a hypolipemic agent. This study explores the lipid-lowering effects of asiaticoside, focusing on its mechanism of action and pharmacological properties. In silico analysis showed a high activation probability (pa=0.934) for asiaticoside, indicating its strong potential to interact with targets involved in lipid metabolism, such as PPAR-α, and reduce blood lipid levels. Additionally, its low inhibition probability (pi=0.003) suggests minimal risk for non-specific biological interference, making it a promising candidate for therapeutic use with a favorable safety profile. Asiaticoside’s antioxidant and anti-inflammatory properties further enhance its potential for cardiovascular protection by reducing oxidative stress, a key factor in atherosclerosis. While preliminary in silico results are promising, further in vitro and in vivo studies are required to confirm its efficacy, safety, and pharmacokinetics. Overall, asiaticoside represents a promising natural agent for managing hyperlipidemia and related metabolic disorders, offering an alternative to conventional synthetic therapies.

Copyrights © 2024






Journal Info

Abbrev

COMORBID

Publisher

Subject

Biochemistry, Genetics & Molecular Biology Medicine & Pharmacology Neuroscience Nursing

Description

About the Journal PHARMACOLOGY, MEDICAL REPORTS, ORTHOPEDIC, AND ILLNESS DETAILS (COMORBID) is an international, modern, general medical publication that publishes research on all aspects of medicine, from fundamental research to significant clinical trials and cost-effectiveness analyses. We ...